This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
A method for personalizing treatment for relapsed AML
![Credit: Unsplash/CC0 Public Domain medical research](https://scx1.b-cdn.net/csz/news/800a/2022/medical-research-2.jpg)
A cellular profiling method called dynamic BH3 profiling (DBP), developed by investigators at Dana-Farber Cancer Institute, has the potential to help guide personalized treatment for relapsed, drug-resistant acute myeloid leukemia (AML), according to a new study published in Blood Cancer Discovery.
Using patient-derived xenograft models of AML in mice, Dana-Farber investigators, in collaboration with Shruti Bhatt, Ph.D., and researchers at the National University in Singapore, found that a reduction in the signaling involved in programmed cell death—called mitochondrial apoptotic priming—plays a role in drug resistance alongside other factors, such as acquired genetic mutations.
The team treated the models with a panel of targeted medicines for AML and profiled the treated cells using DBP. The test assesses the signaling associated with cell death and provides an indicator of a drug's potential to overcome resistance. The method predicted a response to drugs in animal models of AML and in human patients.
Patients with relapsed AML have few treatment options because the disease often resists a broad range of medicines. This study shows that a cellular profiling method called DBP could provide a rapid and personalized mechanism for selecting potentially active medicines for patients. This possibility is being explored in a phase 2 prospective clinical trial at Dana-Farber that will use DBP to select therapies for patients with relapsed AML.
More information: Elyse A. Olesinski et al, Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts, Blood Cancer Discovery (2024). DOI: 10.1158/2643-3230.BCD-24-0001